TherapeuticsMD, Inc. (TXMD) |
1.04 -0.02 (-1.89%) 10-10 16:00 |
Open: | 1.09 |
High: | 1.09 |
Low: | 1.04 |
Volume: | 26,044 |
Market Cap: | 12(M) |
PE Ratio: | -20.8 |
Exchange: | NASDAQ Global Select |
Industry: | Drug Manufacturers - Specialty & Generic |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 1.24 |
Resistance 1: | 1.14 |
Pivot price: | 1.07 |
Support 1: | 0.99 |
Support 2: | 0.82 |
52w High: | 2.44 |
52w Low: | 0.7 |
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
EPS | -0.050 |
Book Value | 2.360 |
PEG Ratio | 0.00 |
Gross Profit | 0.221 |
Profit Margin (%) | -17.94 |
Operating Margin (%) | -33.51 |
Return on Assets (ttm) | -3.6 |
Return on Equity (ttm) | -2.0 |
Thu, 21 Aug 2025
TherapeuticsMD Reports Improved Q2 2025 Results - TipRanks
Wed, 13 Aug 2025
TherapeuticsMD Announces Second Quarter 2025 Financial Results - BioSpace
Tue, 15 Apr 2025
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
Fri, 03 Jan 2025
3 Promising US Penny Stocks With Over $9M Market Cap - simplywall.st
Thu, 17 Oct 2024
TherapeuticsMD Inc. stock remains steady Thursday, underperforms market - MarketWatch
Tue, 23 May 2023
TherapeuticsMD: From Fallen And Forgotten To Cash Cow - Seeking Alpha
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |